Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > “Low dose docetaxel”

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Oct 11, 2022 4:40pm

71 Views

Post# 35018150

RE:RE:RE:RE:RE:“Low dose docetaxel”

Actualy one share of Thera could not even get you a bag on Chetos right now ;-<

Biobob wrote: At the moment the market is pricing nothing.. Th1902 is worth nothing... so expectations are for nothing. They only need to become one of the 45 other Fast track companies in Onco... anything that points to that will be worth more than the Chocolate bar money we have atm...

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"